Organon ANZ certified as a Family Inclusive Workplace
November 1, 2021 11:36 am EDT
Organon’s commitment to a ‘people first’ culture as the foundation for its business has been recognised by Family Friendly Workplaces, with its recent certification as a Family Inclusive Workplace.
Organon’s commitment to a ‘people first’ culture as the foundation for its business has been recognised by Family Friendly Workplaces, with its recent certification as a Family Inclusive Workplace. Family Friendly Workplaces is a joint initiative of Parents at Work and UNICEF Australia, and measures workplaces against standards developed to encourage employers to benchmark their own internal policies against nationally recognised best practices.
One of our priorities when we formed was to give our Founders a voice through employee resource groups (ERGs). The Families@Work ERG were keen to benchmark how Organon was positioned in living up to its commitment to people first, as well as to explore opportunities to consistently aim for ongoing improvement.
Tim Cogin, Director Fertility, Organon ANZ, is the sponsor for the Families@Work ERG, commented, “We are incredibly proud that we have been able to achieve certification as a Family Friendly Workplace in our first four months since establishing as a company. We are in unique times of high stress, and never before has work and family life been so closely integrated. We always want our people to feel good about balancing their work priorities with their family priorities. We know that family comes first, and it is important that workplaces reflect this and adapt accordingly.”
Organon recognises the need to support families in all their forms and has policies to bring this to life for every employee. Initiatives such as the Gift of Time which allowed time off for parents who home-schooled children during the COVID lockdowns and encouraged all employees to take time during the workday to focus on their own health and wellbeing; Focus Fridays which discourages meetings on Fridays and enables a 3pm finish, so that our Founders can focus on deep thinking and completing work without the pressure of meetings; and a unique Principles-based Work @ Organon approach to office attendance are demonstrations of our recognition that families come in all shapes and sizes and vary depending on life stages. We also have plans to continue to evolve our offering over time, and with input from our Founders.
Sophie Althans, Director HR with Organon ANZ shares her perspective on the impact of supporting Founders in all their unique requirements. “I’m proud of the unique people first culture that we actively foster in every decision we make. Embracing flexibility and being open with how our teams work and evolve has a significant correlation with our strong employee engagement across a range of measures. We continue to foster an agile environment in which all Founders have a sense of belonging and bring their valuable diverse perspectives in wholeheartedly embracing Organon’s values.
Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.
Forward-Looking Statement of Organon
Except for historical information herein, this news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).